SEC Form 4 · accession 0001193125-26-297558
Monte Rosa Therapeutics, Inc. · GLUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sharon Townson
Officer — Chief Scientific Officer
Period of report
Jul 6, 2026
Accepted (ET)
Jul 7, 2026 · 4:41 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001826457
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 6, 2026 | M | 6,000 | $6.14 | A | 73,845 | D | |
| Common StockF2 | Jul 6, 2026 | S | 5,600 | $23.2495 | D | 68,245 | D | |
| Common Stock | Jul 6, 2026 | S | 400 | $24.13 | D | 67,845 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F3 | $6.14 | Jul 6, 2026 | M | 6,000 | D | — | Apr 12, 2031 | Common Stock | 6,000 | 197,290 | D |
Explanation of responses
- F1These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2026.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.97 to $23.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3The shares underlying this option are fully vested and exercisable.